Program
tapinarof
Also written as “Tapinarof cream, 1%”, “tapinarof cream, 1%” and “WBI-1001”.
Its studies are mostly in Psoriasis · Dermatitis, Atopic · Skin Diseases, led by 5 companies.
Drug pageTapinarof: every studyMany companies study it; this page follows only the 25 they lead. All 34 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Organonits history only | 121 open or running | phase 4since Dec 26, 2022 | May 16, 2019 | Aug 2027phase 3 · NCT07265479 |
| GlaxoSmithKlineits history only | 80 open or running | phase 3since Jun 27, 2017 | Oct 31, 2013 | none ahead |
| Welichem Biotechits history only | 30 open or running | phase 2since Feb 3, 2009 | Feb 3, 2009 | none ahead |
| Sun Pharmaceutical Industriesits history only | 10 open or running | phase 1since Apr 15, 2026 | Apr 15, 2026 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 3since Dec 16, 2024 | Dec 16, 2024 | none ahead |
Also a collaborator on its studies: Teva Pharmaceuticals, IQVIA Biotech, PPD DEVELOPMENT, LP, Q2 Solutions and iCardiac Technologies.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 10 earlier studies, Feb 3, 2009 to Jun 27, 2017.
- Dec 9, 2016Named tapinarofINNProposed as its International Nonproprietary Name in WHO's List 116 · before, WBI-1001
- Jun 27, 2017Phase 1 study in PsoriasisGlaxoSmithKline · NCT03201978
- May 16, 2019Organon’s first study: phase 3 study in PsoriasisNew to OrganonOrganon · NCT03956355 · 510 enrolled · United States, Canada
- Jun 10, 2019Phase 3 study in PsoriasisOrganon · NCT03983980 · 515 enrolled · United States, Canada
- Jul 23, 2019Phase 3 study in PsoriasisOrganon · NCT04053387 · 763 enrolled · United States, Canada
- Jul 24, 2019Phase 2 study in Plaque PsoriasisOrganon · NCT04042103 · 21 enrolled · United States
- Aug 16, 20212 phase 3 studies in Dermatitis, AtopicOrganon · NCT05014568, NCT05032859
- Oct 28, 20212 phase 3 studiesOrganon · NCT05172726, NCT05142774
- Nov 8, 2021Phase 2 study in Dermatitis, AtopicOrganon · NCT05186805 · 36 enrolled · United States, Canada
- Dec 26, 2022Phase 4 study in PsoriasisOrganon · NCT05680740 · 34 enrolled · United States
- Mar 14, 2023Phase 4 study in PsoriasisOrganon · NCT05789576 · 31 enrolled · United States
- Dec 16, 2024Teva Pharmaceutical Industries’ first study: phase 3 study in Skin DiseasesNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT06742957 · 560 enrolled · United States
- Nov 21, 2025Phase 3 study in Dermatitis, AtopicOrganon · NCT07265479 · 187 enrolled · United States, Canada
- Apr 15, 2026Sun Pharmaceutical Industries’ first study: phase 1 study in Plaque PsoriasisNew to Sun Pharmaceutical IndustriesSun Pharmaceutical Industries · NCT07546214 · 575 enrolled · United States
- Oct 5, 2026Phase 3 study suspendedStudy stoppedNCT07265479
Ahead
- Aug 2027Primary completion: phase 3 study in Dermatitis, AtopicOrganon · NCT07265479
TargetBeta
“Aryl hydrocarbon receptor agonist”ChEMBL 37, by rule
Studies
All 25 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07546214Plaque Psoriasis · United States | 1 | Completed | Sun Pharmaceutical Industries | Mar 18, 2026 | 575 |
| NCT07265479Dermatitis, Atopic · United States, Canada | 3 | Active, not recruiting | Organon | Aug 2027 | 187 |
| NCT06742957Skin Diseases · United States | 3 | Completed | Teva Pharmaceutical Industries | Oct 7, 2025 | 560 |
| NCT05789576Psoriasis · United States | 4 | Completed | Organon | Jun 30, 2023 | 31 |
| NCT05680740Psoriasis · United States | 4 | Completed | Organon | May 18, 2023 | 34 |
| NCT05186805Dermatitis, Atopic · United States, Canada | 2 | Completed | Organon | Aug 24, 2022 | 36 |
| NCT05142774Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Feb 29, 2024 | 728 |
| NCT05172726Plaque Psoriasis · United States, Canada | 3 | Completed | Organon | Oct 14, 2026 | 58 |
| NCT05032859Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Feb 3, 2023 | 406 |
| NCT05014568Dermatitis, Atopic · United States, Canada | 3 | Completed | Organon | Mar 30, 2023 | 407 |
| NCT04042103Plaque Psoriasis · United States | 2 | Completed | Organon | Jan 9, 2020 | 21 |
| NCT04053387Psoriasis · United States, Canada | 3 | Completed | Organon | Apr 6, 2021 | 763 |
| NCT03983980Psoriasis · United States, Canada | 3 | Completed | Organon | May 13, 2020 | 515 |
| NCT03956355Psoriasis · United States, Canada | 3 | Completed | Organon | May 26, 2020 | 510 |
| NCT03202004Psoriasis | 3 | Withdrawn | GlaxoSmithKline | Sep 28, 2018 | 0 |
| NCT03201978Psoriasis | 1 | Withdrawn | GlaxoSmithKline | May 15, 2018 | 0 |
| NCT02564055Dermatitis, Atopic · United States, Canada, Japan | 2 | Completed | GlaxoSmithKline | Jan 1, 2017 | 247 |
| NCT02564042Psoriasis · United States, Canada, Japan | 2 | Completed | GlaxoSmithKline | Oct 1, 2016 | 227 |
| NCT02637206Dermatitis, Atopic · Japan | 1 | Completed | GlaxoSmithKline | Dec 2, 2015 | 26 |
| NCT02466152Dermatitis, Atopic · Canada | 1 | Completed | GlaxoSmithKline | Oct 27, 2015 | 11 |
| NCT02411162Dermatitis, Atopic · United States | 1 | Completed | GlaxoSmithKline | Sep 24, 2015 | 15 |
| NCT01984775Psoriasis · United States, Germany | 1 | Completed | GlaxoSmithKline | Jul 2, 2014 | 52 |
| NCT01098734Dermatitis, Atopic · Canada | 2 | Completed | Welichem Biotech | Oct 2010 | 148 |
| NCT01098721Psoriasis | 2 | Completed | Welichem Biotech | Sep 2010 | 61 |
| NCT00837551Dermatitis, Atopic · Canada | 2 | Completed | Welichem Biotech | Jun 2008 | 36 |
How it is read
Names in the registry
- “Tapinarof cream, 1%”, 4 entries
- “tapinarof cream, 1%”, 4 entries
- “WBI-1001”, 3 entries
- “Tapinarof”, 2 entries
- “GSK2894512 1% Cream”, 2 entries
Codes read as this program: GSK2894512.
Conditions, from the studies’ own filings
- Psoriasis, 13 studies
- Dermatitis, Atopic, 11 studies
- Skin Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.